Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Collaboration To Conduct A Clinical Trial Of TB Vaccine Candidate In People Living With HIV
The Aeras Global TB Vaccine Foundation (Aeras) has announced a new collaboration with The Aurum Institute on the first study to test the AERAS-402/Crucell Ad35 tuberculosis (TB) vaccine candidate for safety in people living with the human immunodeficiency virus (HIV). Aurum will conduct this trial in people living with HIV at its clinical trial site near Johannesburg, South Africa. The Medicines Control Council of South Africa and two Independent Ethics Committees in South Africa have given approval to test the vaccine in South Africa. AERAS-402/Crucell Ad35 has been previously tested for safety in healthy adults in the United States and HIV-negative adults and infants in South Africa.

One Step Closer To An Artificial Nerve Cell
Scientists at the Swedish medical university Karolinska Institutet and Linkç¶ping University are well on the way to creating the first artificial nerve cell that can communicate specifically with nerve cells in the body using neurotransmitters. The technology has been published in an article in Nature Materials.
News of the day
Cambodia Health Officials Expand HIV/AIDS Prevention Education To Primary Schools
The Cambodian Ministry of Health has begun training primary education teachers in 12 provinces on HIV/AIDS prevention education, the Phnom Penh Post reports. Health officials said that although children in primary school are not seen as a high-risk population, they need to be educated on the disease. Mean Chhi Vun -- director of the National Center for HIV/AIDS, Dermatology and STDs -- said the students "are a group of people we have to pay attention to because they ... will be the backbone of the nation." Secondary-school aged students currently are receiving HIV/AIDS education, and the programs are being used as a model for the new primary school initiative, according to Pen Saroeun, director of the Ministry of Education"s School Health Department. Some health officials have said that young people are becoming increasingly at risk for HIV, and most outreach efforts target commercial sex workers and their clients and not young people, the Post reports. Saroeun noted that the HIV/AIDS prevention education program has been successful in secondary schools and is the reason the ministry decided to launch the program in primary schools, adding that many students drop out before reaching secondary school. He said, "We will teach them basic knowledge about HIV/AIDS and life skills, such as negotiation skills, how to say "no," goal setting, and how to provide care and support to people living with HIV/AIDS." The ministry plans to double the $100,000 it allocated to HIV/AIDS education spending last year with additional funding from the United Nations Population Fund, according to Saroeun. He added, "If we are successful in those 12 provinces, then we will do it in the other provinces" (Kunthear, Phnom Penh Post, 5/19).
Medical Devices

Radiant Research, Inc. Prepares For Upcoming H1N1 Vaccine Trials

Radiant Research, Inc. announced that it is actively recruiting subjects and establishing operational plans for upcoming H1N1 vaccine trials. The World Health Organization declared the H1N1 influenza outbreak a pandemic, and the CDC has shipped virus samples to several manufacturers with the hope of having vaccine available to the general public by the fall. Manufacturers will need to complete clinical trials prior to release of vaccine to the public. "Our research sites are ideal for this type of clinical trial," said Julie McHugh, Vice President of Late Phase Clinical Research, Radiant Research, Inc. "We have conducted over 200 vaccine trials and enrolled thousands of subjects into these trials in the past five years. We know how to enroll these trials quickly and efficiently, and we enforce the standards that ensure quality data collection." "We have over a million subjects in our database and they are both familiar with the research process and very interested in this type of trial," said Michael Kritschgau, Vice President of Radiant Recruitment. "We are currently making contact with these potential subjects so we can be ready to enroll once the manufacturers are ready to move to the clinical trials stage. We anticipate that companies producing the vaccine will soon be reaching out to various research. Radiant Research, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009